ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Benefits and Risks of Induction Immunosuppression Therapy in Pediatric Liver Transplantation

T. Bittermann, P. Abt

University of Pennsylvania, Philadelphia, PA

Meeting: 2022 American Transplant Congress

Abstract number: 1457

Keywords: Induction therapy, Liver, Pediatric

Topic: Clinical Science » Liver » 61 - Liver: Pediatrics

Session Information

Session Name: Liver: Pediatrics

Session Type: Poster Abstract

Date: Monday, June 6, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: To investigate trends in induction therapy use in pediatric liver transplantation (LT) in the U.S. and evaluate the potential benefits and risks of induction immunosuppression in this population.

*Methods: This is a retrospective cohort study of 2,748 pediatric (<18 years) first LT alone recipients at 24 centers between 2006-2017 using data from the Pediatric Health Information System (PHIS) linked to the United Network for Organ Sharing database. Induction therapy was captured using day-by-day inpatient pharmacy billing data from PHIS. Clinical outcomes were ascertained using International Classification of Diseases diagnosis codes in PHIS. The association of induction therapy (none or steroid only vs IL2 receptor antagonist (IL2Ra) vs anti-thymocyte globulin (ATG) vs other or combination) with graft and patient survival was evaluated with multivariable time-to-event analysis. Mixed-effects logistic regression was used to study its association with acute rejection (AR) and opportunistic infections (OI) in the first year and post-transplant lymphoproliferative disease (PTLD) in the first two years post-LT.

*Results: Overall, 58.6% received none/steroid-only, 28.1% IL2Ra, 10.9% ATG and 2.5% other/combination induction. Children receiving ATG were more often older (p<0.001) and on dialysis at LT (p<0.001). Induction practices correlated with pediatric LT experience: e.g., 57.4% of recipients at low (<7 LTs/year) volume centers received IL2Ra compared to 23.2% at intermediate (7-14 LTs/year) and 24.3% at high (15+ LTs/year) volume centers (p<0.001 overall). There was little change in practice over time: e.g., 27.0% received IL2Ra in 2005 versus 32.0% in 2017, while 13.8% received ATG in 2005 versus 11.2% in 2017 (p=0.012). In multivariable analyses, observed benefits of induction therapy included improved patient and graft survival with ATG vs none/steroid-only induction among non-tumor recipients (n=2,455) with adjusted HRs of 0.56 (p=0.043) and 0.56 (p=0.002), respectively, and reduced AR during year 1 with IL2Ra with adjusted OR 0.65 (p=0.002). Potential risks included increased readmission for OI during year 1 with ATG (adjusted OR 1.62 vs none/steroid-only, p=0.029), and increased PTLD with IL2Ra (adjusted OR 1.97 vs none/steroid-only; p=0.020).

*Conclusions: In a large pediatric LT cohort, ATG was associated with a more favorable risk-benefit profile than none/steroid-only induction or IL2Ra therapy.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Bittermann T, Abt P. Benefits and Risks of Induction Immunosuppression Therapy in Pediatric Liver Transplantation [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/benefits-and-risks-of-induction-immunosuppression-therapy-in-pediatric-liver-transplantation/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences